Bioventus Q2 2023 net sales $137.1M (-2.3% YoY); Adjusted EBITDA $28.2M (+26%); FY2023 guidance issued

Bioventus Inc.

2023-Q2 EPS reported -$2.29 revenue$256,128,000

Net loss from continuing ops $4.7M ($0.06 EPS loss) vs $7.7M loss in Q2 2022, improved.
Adjusted EBITDA $28.2M, up 26.1% YoY; Non-GAAP EPS $0.14 vs $0.10.
FY2023 guidance: net sales $490-505M, adjusted EBITDA $75-80M, Non-GAAP EPS ($0.24)-($0.20).
Repaid $60.3M of term loan and revolver; net leverage ratio reduced to 4.33 from 5.50.
Closed sale of Wound Business for $31M in net proceeds, used to repay debt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bioventus Inc. reported twelve months ending December 31, 2023 results: revenue $490 million to $505 million, EPS ($0.24) to ($0.20). Guidance initiated.

Period: twelve months ending December 31, 2023
Revenue: $490 million to $505 million
EPS: ($0.24) to ($0.20)
Guidance: initiated
Result: guidance update

Exact text from the filing

For the twelve months ending December 31, 2023, the Company expects: • Net sales of $490 million to $505 million • Adjusted EBITDA* of $75 million to $80 million • Non-GAAP EPS* of ($0.24) to ($0.20)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Bioventus Inc. reported three and six months ended July 1, 2023 results: revenue $137.1 million, net income $4.7 million, EPS $0.06. Guidance initiated.

Period: three and six months ended July 1, 2023
Revenue: $137.1 million
Net income: $4.7 million
EPS: $0.06
Guidance: initiated
Result: reported results

Exact text from the filing

a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: • Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or

View on SEC.gov

Browse all earnings releases →

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-027947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.